Specialty Areas:
Non-malignant hematology, primarily bleeding disorders and sickle cell disease.
Education:
Fellow, University of North Carolina Hospitals, Medical Hematology, July 2017 – June 2020
Fellow, University of North Carolina Hospitals, Pediatric Hematology and Oncology, July, 2016 – June 2020
Resident, University of Rochester Medical Center, Internal Medicine and Pediatrics, July, 2012 – June 2016
MD, The Ohio State University College of Medicine, Columbus, OH, June 2012
BA, German, Cum Laude, University of Utah. Salt Lake City, UT, August 2008
Research Interests:
I am interested in the interaction between endothelium and coagulation proteins as well as blood cells. I have recently presented data showing an increase of factor Xa generation on endothelium in the presence of emicizumab and factor IXa. I am active in investigating the mechanism of thrombosis and thrombotic microangiopathy in the use of emicizumab and have an interest in improving the treatment of breakthrough bleeding in patients on emicizumab. I am more generally interested in the development of systems that can shed light on the mechanisms and complications of emerging, non-factor therapies for hemophilia.
Awards and Grants:
UNC Benign Hematology T32 Grant recipient (2018-2020)
NHF-Takeda Clinical Fellowship Award recipient (2020-Present)
ASH Research Restart Award (1/2021-Present)
Publications:
Chen SL, Ellsworth P, Kasthuri RS, Moll S, Ma AD, Key NS. Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. Haemophilia. 2021 Jul;27(4):e585-e588. doi: 10.1111/hae.14335. Epub 2021 May 29. PMID: 34050698.
Ellsworth P and Little JA. Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark. Lancet Haematol. 2021 May;8(5):e307-e309. doi: 10.1016/S2352-3026(21)00100-9. PMID: 33894164.
Ellsworth P, Chen S, Key NS, Kasthuri RS, Mooberry MJ, and Ma AD. Recombinant Porcine FVIII for Bleed Treatment in Acquired Hemophilia: Findings from a Single-Center Cohort of 18 Patients. Blood Adv. 2020 Dec 22;4(24):6240-6249. doi: 10.1182/bloodadvances.2020002977. PMID: 33351122; PMCID: PMC7756980.
Ellsworth P, Chen S, Abajas YL, Moll S, Key NS, and Ma AD. Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia A Inhibitor Patients: Dosing Strategies and Efficacy. Haemophilia. 2020 Aug 25. doi: 10.1111/hae.14111. Epub ahead of print. PMID: 32842162.
Sparkenbaugh EM, Kasztan M, Henderson M, Ellsworth P, Wilson K, Reeves B, Key NS, Strickland S, McCrae K, Pollock DM, Pawlinski R. High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. JTH. 2020 June.
Noubouossie DF, Henderson MW, Mooberry M, Ilich A, Ellsworth P, Piegore M, Skinner SC, Pawlinski R, Welsby I, Renné T, Hoffman M, Monroe DM, Key NS. Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood. 2020 Mar 5;135(10):755-765. doi: 10.1182/blood.2019001643. PMID: 31971571; PMCID: PMC7059516.
Wilson S, Ellsworth P, Key NS. Pregnancy in sickle cell trait: what we do and don’t know. Br J Haematol. 2020 Feb 17. doi: 10.1111/bjh.16518. Epub ahead of print. PMID: 32064587.
Ilich A, Noubouossie DF, Henderson M, Ellsworth P, Betbadal KF, Campello E, Meeks S, Dunn A, Park MS, Pawlinski R, Simioni P, Shapiro A, Key NS. Development and application of global assays of hyper- and hypofibrinolysis. Res Pract Thromb Haemost. 2019 Nov 6;4(1):46-53. doi: 10.1002/rth2.12275. PMID: 31989084; PMCID: PMC6971323.
Faes C, Ilich A, Sotiaux A, Sparkenbaugh EM, Henderson MW, Buczek L, Beckman JD, Ellsworth P, Noubouossie DF, Bhoopat L, Piegore M, Renoux C, Bergmeier W, Park Y, Ataga KI, Cooley BC, Wolberg AS, Key NS, Pawlinski R. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood. 2019 Apr 05.
